Kết quả điều trị ung thư cổ tử cung giai đoạn tiến triển, tái phát, di căn bằng phác đồ hóa chất paclitaxel–platin kết hợp bevacizumab tại bệnh viện Ung Bướu Hà Nội=Treatment outcomes of patients with progressive, recurrent, metastatic cervical cancer using TC chemotherapy regimen plus bevacizumab at Hanoi Oncology hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Hải Duyên Đinh, Văn Quảng Lê

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.134-141

Bộ sưu tập: Metadata

ID: 478127

Thêm vào giỏ

Đánh giá kết quả điều trị và tác dụng không mong muốn của phác đồ paclitaxel – platin kết hợp bevacizumab trên bệnh nhân ung thư cổ tử cung giai đoạn tiến triển, tái phát, di căn tại bệnh viện Ung Bướu Hà Nội. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả hồi cứu kết hợp tiến cứu tiến hành trên bệnh nhân ung thư cổ tử cung tái phát, tiến triển, di căn được điều trị phác đồ TC (paclitaxel-carboplatin/cisplatin) kết hợp bevacizumab tại bệnh viện Ung Bướu Hà Nội từ 01/2020 đến 01/2024. Kết quả: 51 bệnh nhân dủ tiêu chuẩn tham gia nghiên cứu. Bệnh nhân tái phát sau điều trị hay gặp nhất ở giai đoạn III là 18/51 bệnh nhân, chiếm 35,3%. Có 9/51 (17,6%) bệnh nhân di căn xa ngay tại thời điểm chẩn đoán. Về đáp ứng, 11/51 (21,5%) bệnh nhân đạt đáp ứng hoàn toàn, 28/51 (54,9%) bệnh nhân đạt đáp ứng một phần, tỷ lệ bệnh nhân đạt kiểm soát bệnh là 88,2%. Trung vị thời gian sống thêm bệnh không tiến triển (PFS) là 9,2 tháng, trung vị thời gian sống thêm toàn bộ (OS) là 19,2 tháng. Tác dụng không mong muốn chủ yếu gặp ở độ 1 và 2. Các tác dụng không mong muốn thường gặp là buồn nôn, hạ bạch cầu trung tính, tiêu chảy và thiếu máu, lần lượt là 21/51 (41,2%), 18/51 (35,3%), 15/51 (29,4%) và 14/51 (27,5%) bệnh nhân. Ghi nhận 7/51 (13,7%) bệnh nhân có chảy máu và 2/51 (3,9%) bệnh nhân có THA độ 2 trong quá trình điều trị bevacizumab. Kết luận: Phác đồ paclitaxel-platin kết hợp bevacizumab cho kết quả điều trị khả quan và tương đối an toàn.To evaluate the treatment outcomes and toxicity of the TC chemotherapy regimen plus bevacizumab in patients with advanced, recurrent, and metastatic cervical cancer at Hanoi Oncology Hospital. Subjects and Methods: A retrospective and prospective descriptive study was conducted on patients with recurrent, advanced, metastatic cervical cancer treated with TC regimen (paclitaxel-carboplatin/cisplatin) combined with bevacizumab at Hanoi Oncology Hospital from January 2020 to January 2024. Results: 51 eligible patients were enrolled. Patients who relapsed after treatment were most commonly in stage III, for 35.3% (18/51). There were 9/51 (17.6%) patients with distant metastasis at the time of diagnosis. Regarding response, 11/51 (21.5%) patients achieved complete response, 28/51 (54.9%) patients achieved partial response, and the clinical benefit rate was 88.2%. The median progression-free survival (PFS) was 9.2 months, and the median overall survival (OS) was 19.2 months. Adverse events were mainly grade 1 and 2. Common adverse events were nausea, neutropenia, diarrhea, and anemia, occurring in 21/51 (41.2%), 18/51 (35.3%), 15/51 (29.4%), and 14/51 (27.5%) patients, respectively. Seven patients (13.7%) had bleeding and 2/51 (3.9%) patients had grade 2 hypertension during bevacizumab treatment. Conclusion: The regimen yielded favorable treatment outcomes and was relatively safe.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR